Perlecan, a multidomain heparan sulfate proteoglycan (PG), is an intrinsic component of basement membranes and exaacellular matrices. We used a prokaryotic expression vector to generate fusion proteins encoding various domains of human perlecan protein core and these recombinant proteins were used as immunogens to produa mouse anti-human monoclonal antibodies (MAb) . One MAb, designated 7B5, was characterized by Western blotting and ELISA and was shown to react specific?ly with the laminin-like region of perlecan (Domain III) but not with two other fusion proteins encoding Domain II or V. This perlecan epitope was detected by immunoenzymatic staining in the basement membranes ofhuman times including pituitary gland, skin, breast, thymus, prosrate, colon, l i q paaaeas, spleen, heart,
Introduction
Complex multivalent proteoglycans (PGs) are produced by almost every cell in the body. They exhibit a diverse range of forms and functions and play pivotal roles in tissue architecture and development (1-3) by participating in a wide variety of cellular processes including migration, adhesion, and proliferation (4) and the regulation of growth factor activities (5). Perlecan, a heparan sulfate PG, is a major component of basement membranes in mammalian tissues. It is one of the largest single polypeptide structures in the body, with a protein core of 467 KD as deduced from cDNA se-' Supported by NIH grants . RVI is the recipient of a Faculty Research Award (FRA-376) from the American Cancer Society. ADM was the recipient ofa Wcllcome 'Iiust Research 'Ihvel Grant. * Correspondence to: R. V. Iotzo, Dept. of Pathology and Cell Biology, Thomas Jefferson U,, 249 Jefferson Alumni Hall, 1020 Locust St., Philadelphia, PA 19107. and lung. All vascular basement membranes tested contained this gene product. In addition, sinusoidal vessels of liver, spleen, lymph nodes, and pituitary gland expressed high levels of perlecan in the subendothelial region. In situ hybridization, Using as probe the same human cDNA-enroding Domain III, localized perlecan " A to specific cell types within the tisfues and demonstrated that in skin, perlecan appears to be synthesized exclusively by ~~~e~t i v e tissue cells in the dermal layer. The availability of MAb against precise regions of human perlecan wilJ allow the investigation of this gene product in normal and diseased states. ( J Histodiem Cytochem &:239-249, 1994) KEY WORDS: Human; Pcrlecan; Hepann sulfate protcoglycan; Basement membrane; Immunolocalization; In situ hybridization.
quencing. The site of heparan sulfate linkage is predicted to be at the amino terminus of the protein by the presence of consensus attachment sequences in the first protein domain (6,7) and the appearance on rotary shadowing of a cluster of glycosaminoglycan (GAG) chains at one end ofthe isolated molecule (8) . The remainder of the protein core can be subdivided into four major distinct modules with sequence similarities to various domains of laminin, the low-density lipoprotein receptor, and neural cell adhesion molecules (reviewed in 9).
First described in extracts of the murine Engelbreth-Holm-Swarm (EHS) tumor matrix (lo), heparan sulfate PGs with large (>400 KD) protein cores have since been described in human colon carcinoma cells (11), L2 rat yolk sac tumor (12), bovine endothelial cells (13), human lung fibroblasts (14), human fibrosarcoma cells (7). bovine lens epithelial cells (15), and human corneal epithelial cells (16) . Published evidence also suggests that the perlecan protein core may be substituted with both heparan and dermatan sulfate in human placenta (17) or with heparankhondroitin sulfate in EHS tumor matrix (18) . human corneal fibroblasts (16) . and a cell line that we have recently established from tissue explants of EHS tumor (19) . Antisera raised against thcx various molecules have becn widely used to investigate the distribution of perlecan in human tissues and in other species (6.15.20). The identity of many of the PGs listed above as perlecan is largely based on immunological crossreactivity with antibodies primarily raixd against the EHS tumor perkcan. Although there is clear evidence in some cases of total identity, in others it is not absolutely clear if these related PGs are all products of the same gene. Additional smaller PGs of basement membranes can be grouped into those thought to be proteolytically processed forms of a perkcan precursor (21) and those with immunological and structural differences (18.22-25) . More detailed analysis of the distribution and relationships of these complex macromolecules has p m n difficult, since none ofthe antibodies characterized to date have had their interactions localized to any specific sites on PG protein cores.
We have recently cloned the entire human perlecan EDNA (6) and the availability of cDNA clones encompassing each domain prompted us to adopt an alternative approach to this typc of study. By introducing portions of perlecan cDNA into an expression vector and producing recombinant fusion proteins. it is possible to obtain antibodies directed against a specific region of the protein core and definitively reactive with the product of the pcrlecan gene. We utilized this approach to raix a new specific monoclonal antibody (MAb) against Domain 111 of human perlecan and examined the distribution of this cpitopc in a wide variety of normal human tissues. In conjunction with the immunoenzymatic study, wc also took advantage of in situ hybridization techniques to investigate the specific sites of perlecan mRNA expression in the various tissue typcs. The results demonstrate the widespread distribution of this cpitope and provide evidence for a cooperative contribution by different cell types to the composition of the extracellular matrices with which they are in contact.
Materials and Methods
Plasmid Conmumion. A cDNA encompassing approximately 70% of perlecan Domain 111. a laminin-like region, was inserted into the pMALc expression vector (New England Biolabs; Beverly. MA). The 2.46 KB HS17, spanning bves 1658-4117 of the perlecan cDNA. was rclewd from pBluexript with EoRI and subcloned into the EcoRI site in the polylinker region ofpM11-c. Corrm orientation ofthc insert and maintenance ofmding frame across the vector/inxrt junction were verified by DNA sequencing as described bdore (6) The expression sysrem supplier's protocol was therefore modified to allow an inclusion body isolation and purification step (26). Briefly. induced bacterial cultures were treated with lysozyme and deoxycholate to lyse the cells and were then centrifuged. The pelleted material was washed m r a l times in 50 mM Tris-HCI, pH 8, 100 mM NaCI. IO mM EDTA containing 0.5% Triton X-100. Washed pellets were solubilized in 8 M urea. 50 mM Tris-HCI, pH 8, 100 mM NaCI, 1 mM EDTA, dialyzed into pMALcolumn buffer (10 mM phosphate. pH 7. 0.5 M NaCI, 1 mM azide, 10 mM 2-mercaptoethanol. 0.5 mM E M A ) and applied to an amylose resin column (New England Biolabs). After washing with column buffer, affinity bound material was specifically eluted with column buffer containing IO mM maltox. Protein eluted from the column was shown by SDS-PAGE to consist of one band of M, 430 KD on naining with Coomassic brilliant blue (Bio-Rad: Richmond, CA) ( Figure 1 ) and was concentrated with Centricon-30 microconcentraton (Amicon: Dulvcn. MA) to 0.5 mglml for immunization.
Immunization and Screening of Hybridomas. Aliquors (50 pg) of the fusion protein were used to immunize mice. After three or four booster injections. serum from the mice was rated for positive immunohisrochemical staining on frozen sections of human kidney. as described below. Immunization was protracted for 8-10 weeks to favor the generation of IgG against the fusion protein. Somatic cell hybridization was performed following standard procedures. Culture medium from clonal populations of hybridomas was tested in an ELISA system for reactivity with fusion pro- Immunodetmion Methods. Western blottings of crude bacterial lysates and purified proteins were prepared by size separation of proteins on 10% SDS-PAGE gels. Proteins were transferred electrophoretically to nitrocellulose (Schleicher & Schuell; Keene. NH) by standard methods (27). The filters were blocked in 4% non-fat dried milk in Tris-buffered saline (TBS) + 0.02% Tween 20 (Sigma) and reacted with MAb 7B5 at a 1:10 dilution of hybridoma culture medium. Bound MAb was visualized with alkaline phosphatase-conjugated goat anti-mouse IgG antibodies (Pierce Chemical; Rockford. IL) using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim Biochemicals; Indianapolis, IN) as substrates.
Frozen sections of surgically obtained human tissues were reacted with MAb 7B5 in a 1:lOO dilution of hybridoma culture medium essentially as described previously (28). Bound primary antibody was reacted with unlabeled rabbit anti-mouse Ig "bridging" antibodies and subsequently with immune complexes of alkaline phosphatase and anti-alkaline phosphatase MAb (APAAP method). Reagents were diluted in TBS and incubated with sections for 60 min. followed by washes in TBS. Signal amplification was achieved by using two layers of bridging antibodies and anti-alkaline phosphatase antibodies (28). The alkaline phosphatase substrate was new fuchsin. Sections were countemai'ned with hematoxylin. MAb 7B5 was also tested on a number of fixed and paraffin-embedded human tissues. After deparaffhization, the sections were incubated with 0.1% pronase (Sigma P-5147) in PBS for 30 min at room temperature, rinsed with deionized distilled water and then with PBS before reaction with the primary MAb and processing as described above. Controls included replacing the primary MAb with PBS or with antibodies against keratin or CD4, a pan-T-cell marker, to demonstrate specific staining distinct from that observed with 7B5 (not shown).
In Situ Hybridization. In situ hybridization was performed using plasmid HS17 containing perlccan EDNA from bases 1658-4117, the same portion of cDNA used for fusion protein expression. Tissues were fixed and processed for hybridization as previously described (29.30). Briefly, 8-pmthick sections from tissues fiied in modified Carnoy's solution at -2O'C and impregnated with amyl acetate-paraffin were digested with proteinase K (Boehringer). post-fixed in formaldehyde, and denatured with formamide. HS17 plasmid was labeled by random priming in the presence of biotin4UTP (31). Hybridization was visualized histochemically with nreptavidin-alkaline phosphatase (Enzo Biochemicals; New York, NY) using 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (Boehringer)= substrates. Hybridization signal was seen as a dark purple precipitate on the sections. Control sections were hybridized with biotin-dUW-labeled plasmid vector alone.
Results

Characterization of a Novel MA6 Against Domain III of Human Perlecan Protein Core
Antibodies secreted into the culture medium of clonal populations of hybridoma cells were tested for their ability to recognize perlecan Domain 111 fusion protein. Clones positive by ELISA were further screened for basement membrane distribution in immunoen- zymatic staining of frozen sections of human kidney. One strongly positive clone, MAb 7B5, was chosen for further analysis. MAb 7B5 was shown by immunoglobulin isotyping to be mouse IgG1. Westem blotting of crude bacterial lysates (Figure 1 ) demonstrated that the epitope recognized by MAb 7B5 was not susceptible to reducing agents and was probably pepti'de in nature, as the fusion protein was expressed as a bacterial cytoplasmic molecule. Furthermore, these studies confirmed the specificity of the MAb to the Domain lios Pharmaceuticals; San Diego, CA) in native or denatured forms in a variety of tests, including ELISA and dot-and Westem blotting (not shown). In the &LISA tests, Domain I11 fusion protein was detectable at coating concentrations as low as 125 ng/ml, whereas laminin remained undetectable at concentrations of up to 5 vg/ml.
Immanokcalization of Perhcan
To establish the sites of perlecan gene expression we undertook a systematic immunoenzymatic study of perlecan in the major vascularized human tissues with MAb 7B5. We describe below the Skin. Skin showed strong immunoreactivity for perlecan at the dermallepidermal junction ( Figure 3A, arrowheads) . Faint reaction was also observed in fibrous strands leading into the underlying dermal region. In addition, positive foci were scattered in the upper dermis and in the perivascular regions. The keratinocytes were consistently negative, a result corroborated by the in situ hybridization studies (cf. Figure 6A ).
Breast. Perlecan was widely distributed in breast tissue, not only within small blood vessels but also throughout the connective tissue stroma and adipose tissue. Interestingly, the mammary epithelial cells were negative, whereas the surrounding myoepithelial cells were strongly positive for expression of perlecan ( Figure 3B , arrowheads).
Genitourinary System. Perlecan staining was present in all the basement membranes of kidney cortex. Reaction was especially prominent in the Bowman's capsule, the tubule basement membranes, and the mesangial mauix ( Figure 3C ). MAb 7B5 also worked on formalin-fixed, paraffin-embedded tissues, but only after mild pronase treatment. As shown in Figure 3D , perlecan can be seen in the same structures as in the frozen tissue and more clearly in the glomerular capillary basement membranes. The medullary region of the kinase showed strong positivity in both the tubule basement membrane and blood vessels (not shown). In prostate and seminal vesicles perlecan was localized with fine detail to subepithelial basement membranes ( Figure 3E, arrowheads) . Again, all the epithelial cells remained constantly negative. However, the prostate nerve plexus and the prostate capsule were strongly positive (not shown).
Placenta. Term placenta contained abundant quantities of perlecan surrounding syncytiotrophoblasts and in subendothelial basement membranes of fetal vessels ( Figure 3F ).
Liver and Gasaointestiaal System. Intense staining was observed in sections of liver ( Figure 4A ). Reactivity was evident in the liver sinusoids and the blood vessels of the portal triads. In exocrine pancreas ( Figure 4B ), perlecan staining delineated the well-formed basement membrane surrounding the pancreatic acini and in the fine interacinar fibrovascular stroma. Normal colon was positive in the basement membrane region, with uniform staining (not shown). In addition, the submucosa was diffusely stained with anti-perlecan antibody, whereas the epithelial cells were consistently negative.
Respiratory System. In the lung, perlecan outlined the alveolar wall and was present in the fibrous septae (not shown). In addition, the microcirculation and the mesothelial basement membrane of the parietal and visceral pleura were positive (not shown).
Cardiopascular and Skeletal Musde Systems. Every blood vessel tested showed strong reaction for perlecan at the subendothelial basement membrane and in some larger vessels at the lumenal endothelial surface. It is noteworthy that after mild pronase treatment perlecan could be clearly visualized within the cytoplasm of endothelial cells (Figure 4C, arrows) . Cardiac (not shown) and skeletal ( Figure 4D , arrowhead) muscle basement membranes were also shown to contain perlecan. Intense staining was also observed in the endocardial and epicardial basement membranes, whereas most of the cardiac myocytes were either totally negative or weakly positive (not shown). These results suggest that other interstitial cells are the source of perlecan biosynthesis in cardiac and skeletal muscle (see below). Peripheral Nerves and Endoaine System. Perlecan was demonstrated in neural tissue by strong positivity of the extracellular matrix surrounding nerve cells ( Figure 4D, arrows) . In a thyroid section from an elderly individual, several dilated thyroid follicles were observed, with perlecan immunostaining localized to the subepithelial basement membranes ( Figure 4E, arrowheads) . Prominent reactivity was seen in the basement membranes surrounding parenchymal cords of the pituitary gland and more intensely in the blood vessels ( Figure 4F ).
Lymphoreticular System. Blood vessels and capsule epithelial basement membranes in the thymus of a newborn normal infant were strongly positive for perlecan. In agreement with the binding in other epithelial organs, the Hassall's corpuscles (which are of epithelial origin) showed no reaction with the MAb (Figure ) A). Small blood vessels of lymph node stained very strongly for perlecan ( Figure 5B ), and faint staining was observed throughout the mass of the lymphoid tissue. At higher magnification, the delicate sinusoidal staining could be seen more clearly (Figure 5C ). Perlecan was found below the capsule of the spleen and along all the sinusoidal tracts of the red pulp ( Figure 5D ). The basement membrane between the keratinizing buccal mucosa and lymphoid tissue of tonsil was strongly positive for perlecan ( Figure 5E , arrowheads). Staining was also present in small blood vessels penetrating the lymphoid aggregates ( Figure 5F ) and in the basement membranes at the interface between these aggregates and the surrounding connective tissues (Figure 5G) . Arteriolar staining was very prominent ( Figures 5G and SH) , and perisinusoidal localization of perlecan was observed again in the lymphoid aggregates ( Figure 5H ).
In Situ Localization of Perlecan %RNA Skin. Strong signal was seen within cells of the upper dermis, particularly those near the dermaUepidermal junction ( Figure 6A , arrowheads). However, no signal was detected in any of the cells of the epidermal strata, which supports the immunoenzymatic localization of perlecan (cf. Figure 3A) .
Liver and Gastrointestinal h c t . In the liver the hepatic parenchyma was essentially negative, in agreement with the observation that hepatocytes do not express perlecan. However, the connective tissue stroma in the portal space region was intensely reactive (not shown). In colon, reaction product indicating perlecan mRNA (Figure 6C ) was restricted to cells of the submucosal stroma and the endothelial cells of blood vessels. Interestingly, the muscularis mucosa ( Figure 6C , asterisk) was negative or faintly positive, indicating that synthesis of perlecan occurs primarily in interstitial connective tissue cells. Chorionic Villus. Trophoblasts of 8-9-week chorionic villi gave intense precipitates, indicating the presence of abundant perlecan transcript ( Figure 6E, arrowheads) , in agreement with previous localization of perlecan in human placenta (6). Cardiac and Skeletal Muscle. We detected no mRNA for perlecan in cardiac (not shown) and skeletal muscle cells (Figure 6F) . This suggests that the perlecan PG present throughout the basement membrane of skeletal and cardiac muscle is synthesized by interstitial connective tissue cells and possibly by capillary endothelial cells.
Discussion
In this study we have defined a new domain-specific immunological probe for the human protein core. With this tool we have localized the perlecan Domain 111 epitope and, by inference, the perlecan PG to all the basement membranes of the human tissues studied. By combining this investigation with in situ hybridization we have been able to distinguish not only the sites ofdeposition of the perlecan protein core but also the cellular sites of synthesis within the tissues.
The ubiquitous disuibution of this molecule in basement membranes suggests that it performs some crucial role(s) in basement membrane structure and/or function. The abundance of the molecule and its ability to interact with other basement membrane components (32-34) and to self-associate (35) appear to support this concept. Described functions for perlecan include anchoring the highly polyanionic GAG chains at the basement membrane and forming part of the complex structural network of the basement membrane (36) although the large size and multidomain structure suggest further multiple activities. Investigated interactions with cells include those with hepatocytes (37,38) and endothelial cells (39). At this point it will be important to differentiate among the species being studied, since the endothelial cell binding appears to be largely RGD-dependenta peptide triplet integrin ligand found in mouse perlecan (40) but not in human (6,7), where this interaction must depend on an altemative mechanism.
An interesting development in perlecan biology is the possible role of this PG in development and function of skeletal muscle. In a recent study by Rogalski et al. (41) , a novel gene product with extensive homology to the perlecan protein core was discovered in the worm Caenorhabditis elegans. Mutations of this gene induced disruption of the skeletal architecture, where the product of the gene is apparently important in muscle fiber anchorage. These results suggest that perlecan is similarly involved in the control of mammalian skeletal muscle function, since this PG is widely distributed in the basement membranes of skeletal and cardiac myocytes. However. we could not detect any perlecan mRNA in skeletal muscle cells by in situ hybridization, indicating that this component of the muscle basement membrane may have been laid down earlier in the development of the muscle fiber, or by another cell lineage. The lack of perlecan transcript in both skeletal and smooth muscle cells ( Figures 6C and 6F) is intriguing, given the localization of the perlecan molecule to muscle basement membranes in this study ( Figure 4D ) and in previous reports (6,20,42). It is often assumed that cells surrounded by or tightly apposed to a basement membrane are responsible for synthesis and deposition of this specialized extracellular matrix. However, as we have found in the course of this investigation, this is not necessarily the case. Unequal contribution by two different cell types to a shared basement membrane can clearly be seen in human skin. By in situ hybridization, we have demonstrated that the perlecan component of the dermal/epidermal basement membrane of mature skin is contributed exclusively by elements of the dermis, not by any of the epidermal cells ( Figure 6A) . In an immunogold labeling study of human skin, Heremans and co-workers (14) noted concenuation of labeling with their panel of anti-fibroblast heparan sulfate PG antibodies on the dermal aspect of the dermallepidermal basement membrane. It is possible that this unequal distribution of epitopes was at least in part a consequence of unilateral deposition of perlecan into the basement membrane by dermal fibroblasts. A similar distribution in adult human skin has also been demonstrated with MAb against EHS perlecan (43). However, in neonatal skin a close association of the epitope with keratinocyte basilar cell membranes was also observed. Another example of this concept can be found in a novel interspecies hybrid model of intestinal development (44) . In this case, the perlecan in the basement membrane of rat/chick epithelial/mesenchymal interfaces was exclusively of epithelial origin. Investigation of the development of these and other similar interfaces should also be amenable to the combination of immunohistochemical and in situ hybridization techniques.
A greater understanding of this cell-specific expression will be achieved with the aid of analysis of the perlecan gene and its promoter, the structure of which has been recently deciphered in our laboratory (45). This large gene has 94 exons and a GC-rich promoter similar to that found in housekeeping and growth regulatory genes.
The distribution of the perlecan protein core was not restricted to basement membranes. We localized immunoreactive perlecan to tissue stroma and regions of organs such as liver, where no patent basement membranes are found (46), confirming our earlier findings (6) and those of others (14.17,20) .
One of the most interesting results of this study was the immunolocalization of perlecan in sinusoidal vessels of lymphoid organs. In a similar manner to that of the liver, there is no recognized basement membrane in these structures. However, a similar "reticular meshwork" has been noted in human thymus immunostained with antibodies against Type IV collagen, laminin, and fibronectin (47). The presence of perlecan in the microcirculation of the immune system indicates the possibility of interactions with lymphocytes as they migrate into the sinusoidal vessels and leave the lymphoid aggregates of the organ. This discovery also suggests a possible role for perlecan in the orderly development of these organs and certainly merits further investigation.
The novel MAb generated for this investigation immunostained all the basement membranes tested, including some, such as those of the pituitary gland, for which we could find only published reports of other basement membrane components (48.49). Some of the positively staining basement membranes. e.g., that of the renal glomerulus, contain on exuaction with highly dissociative compounds only heparan sulfate PGs with protein cores considerably smaller than the predicted perlecan core size of 467 KD. Yet as mentioned above, these smaller species can display considerable immunoreactivity with antisera and antibodies raised against the large low-density perlecan PG, and vice-versa (21). Our results with MAb 7B5 appear to support these findings and suggest that smaller variant forms of perlecan in the glomerular basement membrane should extend to include at least a portion of Domain 111. It is not known whether, after this suggested processing of the perlecan core, the various fragments of the molecule are all present in the basement membrane or only selected ones targeted for further degradation. This new MAb alone cannot distinguish between these possibilities. However, further clarification of this intriguing problem may be achieved by application of this specific probe in conjunction with other similar antibodies raised against the remaining domains of the perlecan protein core. 
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